biotech / news / / Markets Insider
UBS analyst maintained a Buy rating on CSPC Pharmaceutical Group on May 21 and set a price target of HK$10.90.
UBS analyst reaffirmed a Buy rating on CSPC Pharmaceutical Group with a HK$10.90 target.
KEY POINTS
- CSPC shares closed at HK$7.34, significantly below the UBS target price.
- Analyst consensus rates CSPC as Moderate Buy, with a HK$10.42 price target consensus.
- CSPC's quarterly revenue and net profit both declined year-over-year as of December 31.
COMPANIES
Summarized by Newsio from Markets Insider. How we summarize →